SZodixStudyAcademic Library
ShelvesOpen access
Study · an open academic library·Metadata from OpenAlex (CC0)·Shelves·OpenAlex metadata, de-duplicated
Cost-effectiveness analyses using real-world data: an overview of the literature
12 references·0 citing·38 second hop
Cost-effectiveness analyses using real-world data: an overview of the literature (2019)Cost-effectiveness analyses using real-wo…Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies (2017)Policies for Use of Real-Worl…Economic Evaluation in Clinical Trials (2014)Economic Evaluation in Clinic…Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry (2013)Treating to the target of rem…Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments? (2012)Paying for the Orphan Drug Sy…Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers (2010)Linking payment to health out…Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report (2007)Using Real-World Data for Cov…Economic Evaluation in Clinical Trials (2007)Economic Evaluation in Clinic…Methods for the economic evaluation of health care programmes, 3rd ed (2006)Methods for the economic eval…Methods for the Economic Evaluation of Health Care Programmes (2005)Methods for the Economic Eval…Review of guidelines for good practice in decision-analytic modelling in health technology assessment (2004)Review of guidelines for good…Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle (2004)Inclusion of cost effectivene…Cost-Effectiveness in Health and Medicine (1996)Cost-Effectiveness in Health …Cost-Effectiveness Analysis and the Consistency of Decision Making (2001)Health Economic Guidelines—Similarities, Differences and Some Implications (2001)Theory versuspractice: a review of ?willingness-to-pay? in health and health care (2001)Measuring Preferences for Cost-Utility Analysis (2007)Coverage with Evidence Development, Only in Research, Risk Sharing, or Patient Access Scheme? A Framework for Coverage Decisions (2012)Comparing the ICERs in Medicine Reimbursement Submissions to NICE and PBAC—Does the Presence of an Explicit Threshold Affect the ICER Proposed? (2018)Empirical Evidence of Bias (1995)Randomized, Controlled Trials, Observational Studies, and the Hierarchy of Research Designs (2000)Evaluating non-randomised intervention studies (2003)A taxonomy of model structures for economic evaluation of health technologies (2006)Good Practice Guidelines for Decision-Analytic Modelling in Health Technology Assessment (2006)Principles of Good Practice for Decision Analytic Modeling in Health-Care Evaluation: Report of the ISPOR Task Force on Good Research Practices—Modeling Studies (2003)Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: Report of the ISPOR Task Force for Translation and Cultural Adaptation (2005)Key principles for the improved conduct of health technology assessments for resource allocation decisions (2008)What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews (2017)Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making (2018)Three Approaches to Qualitative Content Analysis (2005)Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups (2007)Critical appraisal of nonrandomized studies—A review of recommended and commonly used tools (2018)Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing—Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative (2020)Reproducibility of real-world evidence studies using clinical practice data to inform regulatory and coverage decisions (2022)EQ-SD: a measure of health status from the EuroQol Group (2001)Innovation in the pharmaceutical industry: New estimates of R&D costs (2016)Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses (2016)The estimation of a preference-based measure of health from the SF-36 (2002)Systematic reviews: CRD's guidance for undertaking reviews in health care (2010)International survey on willingness‐to‐pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? (2009)Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report (2015)Health-related quality of life measured using the EQ-5D–5L: South Australian population norms (2016)Conducting Discrete Choice Experiments to Inform Healthcare Decision Making (2008)Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement (2013)Consolidated Health Economic Evaluation Reporting Standards (CHEERS)—Explanation and Elaboration: A Report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force (2013)Managed entry agreements for pharmaceuticals: the European experience (2013)Dealing with uncertainty and high prices of new medicines: A comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden (2014)ESMO European Consortium Study on the availability, out-of-pocket costs and accessibility of antineoplastic medicines in Europe (2016)Non‐parametric methods for cost‐effectiveness analysis: the central limit theorem and the bootstrap compared (2009)Economic evaluation alongside randomised controlled trials: design, conduct, analysis, and reporting (2011)Clinical and Cost-Effectiveness of Therapist-Guided Internet-Delivered Cognitive Behavior Therapy for Older Adults With Symptoms of Depression: A Randomized Controlled Trial (2014)
this work references cited by second hop

References

  • 2005Methods for the Economic Evaluation of Health Care Programmes13,647 cited
  • 1996Cost-Effectiveness in Health and Medicine7,192 cited
  • 2006Methods for the economic evaluation of health care programmes, 3rd ed956 cited
  • 2014Economic Evaluation in Clinical Trials910 cited
  • 2007Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report700 cited
  • 2004Review of guidelines for good practice in decision-analytic modelling in health technology assessment697 cited
  • 2007Economic Evaluation in Clinical Trials366 cited
  • 2010Linking payment to health outcomes: A taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers287 cited
  • 2017Policies for Use of Real-World Data in Health Technology Assessment (HTA): A Comparative Study of Six HTA Agencies206 cited
  • 2004Inclusion of cost effectiveness in licensing requirements of new drugs: the fourth hurdle194 cited
  • 2012Paying for the Orphan Drug System: break or bend? Is it time for a new evaluation system for payers in Europe to take account of new rare disease treatments?171 cited
  • 2013Treating to the target of remission in early rheumatoid arthritis is cost-effective: results of the DREAM registry66 cited

Cited by

No citing works inside the corpus for this window.

Only edges whose both ends are imported exist here. Widen the year window, or show the whole map. Back to the work